Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study
NCT00543868Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2004
- Primary completion
- Aug 2004
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of laropiprant in osteoarthritis (OA) and rheumatoid arthritis (RA) (4 arms), sponsored by Merck & Co. Primary endpoints: Incidence of Stomach and Small Intestine Ulcers at 7 days, Severity of Stomach and Small Intestine Ulcers at 7 days and 1 more. Started Jun 2004; status: completed.
02
Drugs
laropiprant
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00543868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00543868.